The project

Diabetes is a global pandemic, currently affecting around 60 million people in Europe. Hypoglycaemia is a common and serious complication of diabetes, particularly affecting people with diabetes on insulin therapy. Consisting of very low levels of blood glucose, hypoglycaemia can lead to cognitive decline, cardiovascular events and even death.

As much about hypoglycaemia remains unknown, the recently started European research project Hypo-RESOLVE (Hypoglycaemia – Redefining SOLutions for better liVEs) aims to provide researchers and clinicians with more validated data about the condition by:

  • Creating a sustainable clinical database;
  • Conducting studies to better understand the underlying mechanisms of hypoglycaemia;
  • Conducting a series of statistical analyses to define predictors and consequences of hypoglycaemia;
  • Calculating the financial cost in European countries.
Duration
Duration

48 months

Budget
Budget

€ 26.8 Mio

23 partners
23 partners

10 countries

Hypo-RESOLVE brings together 23 partners from 9 European countries and the US. Comprising leading academic experts, pharmaceutical and device manufacturers, as well as patient organisation, the Hypo-RESOLVE consortium includes the full expertise needed to lift the understanding of hypoglycaemia to the next level.

The project is supported with funding of € 26.8 million from the Innovative Medicines Initiative (IMI), a joint undertaking of the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), T1D Exchange, JDRF, International Diabetes Federation (IDF), and the Leona M. and Harry B. Helmsley Charitable Trust.

Download the Hypo-RESOLVE project leaflet.